Company: IXHL
Filing Date: 2025-05-28
Form Type: 424B5
Source: 0001213900-25-047991
Chunk: 0

Company: Incannex Healthcare Inc.
Filing Date: 2025-05-28
Form: 424B5
Chunk 0
---
Filed pursuant to Rule 424(b)(5)

Registration No. 333-283028

Prospectus Supplement

(to Prospectus Supplements dated May 20, 2025 and April 7, 2025, to Prospectus dated November 22, 2024)

<div align='center'>Up to $50,000,000

Shares of Common Stock</div>

This prospectus supplement
(this “Prospectus Supplement”) amends and supplements the information in the prospectus, dated November 22, 2024 (the “Prospectus”),
filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-283284) (the “Registration
Statement”), as previously supplemented by our Prospectus Supplements, dated April 7, 2025 and May 20, 2025 (such Prospectus Supplements
together with the Prospectus, the “Prior Prospectuses”), relating to the offer and sale of shares of our common stock pursuant
to the terms of that certain Sales Agreement, dated April 7, 2025, between the Company and A.G.P./Alliance Global Partners (“A.G.P.”)
(the “Sales Agreement”). This Prospectus Supplement should be read in conjunction with the Prior Prospectuses, and is qualified
by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectuses.
This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectuses and
any future amendments or supplements thereto.

We are filing this Prospectus
Supplement to reflect the amendment and restatement on May 27, 2025, of the Sales Agreement to add Curvature Securities LLC (“Curvature”)
as an additional sales agent. Accordingly, each reference to the terms “Sales Agent” and “A.G.P.” in the Prospectus
Supplement are hereby amended to refer to “Sales Agents” and include Curvature and each reference to the term “Sales
Agreement” in the Prospectus Supplement is hereby amended to refer to the amended and restated sales agreement effective as of the
date of this Prospectus Supplement.

We are also filing this Prospectus
Supplement to amend the Prior Prospectuses to update the amount of shares we are eligible to sell pursuant to such Prospectus. We are
increasing the amount of shares of Common Stock we may offer and sell under the